INSY Insys Therapeutics Inc.

-0.02  -0%
Previous Close 4.93
Open 4.91
Price To Book 2653.26
Market Cap 364664036
Shares 74,269,661
Volume 546,695
Short Ratio
Av. Daily Volume 455,549

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 181172334
  2. 8-K - Current report 181160509
  3. 8-K - Current report 181117042
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181004610
  5. 8-K - Current report 181002493

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due "soon" - company noted December 4, 2018.
Refractory childhood absence epilepsy
Approved January 5, 2012.
Cancer pain
Phase 2 initiated August 2016
Pharmaceutical Cannabidiol (CBD)
Cocaine dependence
Announced approval July 5, 2016.
Dronabinol Oral Solution
AIDS-related anorexia
Phase 3 initiation announced March 2, 2018. Data due 2Q 2019.
Pharmaceutical Cannabidiol (CBD)
Infantile spasms (IS)
CRL issued July 27, 2018.
Moderate to severe postoperative pain after bunionectomy
NDA filing due 1Q 2019 following data from nonclinical juvenile toxicity trial.
Naloxone nasal spray
Opioid overdose

Latest News

  1. Opioid maker Insys paid kickbacks to physician assistant, jury hears
  2. Opioid maker Insys paid physician assistant kickbacks, U.S. jury hears
  3. Physician assistant faces U.S. trial over Insys opioid kickbacks
  4. Alternatives to Watch
  5. Detailed Research: Economic Perspectives on AT&T, JD, EMC Insurance Group, Insys Therapeutics, Medidata Solutions, and Heritage-Crystal Clean — What Drives Growth in Today's Competitive Landscape
  6. These 17 Pot Stocks Were Throttled in November
  7. INSYS Therapeutics Inc (NASDAQ:INSY): Time For A Financial Health Check
  8. INSYS Therapeutics Presents New Clinical Data from Long-Term Safety Study of CBD Oral Solution in Refractory Pediatric Epilepsy
  9. Muddy Waters Research founder Carson Block talks morality shorts
  10. Former Insys executive pleads guilty to opioid bribe scheme
  11. Ex-executive to cooperate with feds in opioid kickback case
  12. 3 Marijuana Stocks to Avoid Like the Plague in December
  13. Former executive at opioid maker Insys to plead guilty
  14. Cannabis Stocks That Could Uptrend
  15. Why Marijuana Stock INSYS Therapeutics Is Down 30% in 2018
  16. It's Time to Throw This Marijuana Stock Away and Never Look Back
  17. Edited Transcript of INSY earnings conference call or presentation 5-Nov-18 10:00pm GMT
  18. Clinical Data from Long-Term Safety-Study of Company’s Pharmaceutical CBD in Refractory Pediatric Epilepsy To Be Presented at American Epilepsy Society Meeting
  19. Company with Technology to Compete with Problematic Opioids